

# OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850 UNITED STATES Phone: +1-888-267-4436 Fax: +1-301-340-8606

techsupport@origene.com

OriGene Technologies GmbH

Schillerstr. 5 32052 Herford GERMANY Phone: +49-5221-34606-0

Phone: +49-5221-34606-Fax: +49-5221-34606-11 info-de@origene.com

# CL090 Monoclonal Antibody to MHC Class II I-Ad - Ascites

Quantity: 0.5 ml

Host / Isotype: Mouse / IgG2a

Clone: 34-5-3S

Immunogen: BDF splenocytes

Donor: C3H splenocytes Fusion Partner: SP2/0-Ag14

Format: State: Lyophilized Ascites filtered to 0.45 mm

Reconstitution: Restore with 0.5 ml of cold distilled water.

Applications: Flow Cytometry.

Other applications not tested. Optimal dilutions are dependent on conditions and

should be determined by the user.

Specificity: This monoclonal antibody specific for cells expressing the Ia antigen coded for by the

A subregion of the d, b, p, and q haplotypes. (ie. I-Ad,b,p,q).

Species: Mouse.

Other species not tested.

Storage: Prior to and following reconstitution store the antibody at -20°C.

Avoid repeated freezing and thawing. Shelf life: one year from despatch.

Product Citations: Purchased from Acris:

1. Ellen Donovan, Brent L. Finley, Ian Kimber, Dennis J. Paustenbach. Data in Brief 9

(2016)388-397.

General Readings: 1. Ozato K, Mayer NM, Sachs DH. Monoclonal antibodies to mouse major

histocompatibility complex antigens. Transplantation. 1982 Sep; 34(3):113-20.

PubMed PMID: 7135466.

2. Ahn, H.J. et al. 1997. A Mechanism Underlying Synergy Between IL-12 and IFN-g-Inducing Factor in Enhanced Production of IFN-g. Journal of Immunology. 159:

2125-2131.

Protocols: CYTOTOXICITY ANALYSIS:

# Method:

- 1. Prepare a cell suspension from the appropriate tissue in Cytotoxicity Medium<sup>a</sup> or equivalent. Remove red cells and dead cells (where necessary) by purification of viable lymphocytes on Lympholyte®-M<sup>b</sup> cell separation medium. After washing, adjust the cell concentration to 1x10e6 cells per ml in Cytotoxicity Medium.
- 2. Add the antibody to a final concentration of 1:80 and mix.
- 3. Incubate for 60 minutes at 4°C.
- 4. Centrifuge to pellet the cells and discard the supernatant.
- 5. Resuspend to the original volume in Low-Tox®-M Rabbit Complement diluted to the appropriate concentration in Cytotoxicity Medium. (Recommended concentration included with each batch of Low-Tox®-M Rabbit Complement.)



- 6. Incubate for 60 minutes at 37° C.
- 7. Place on ice.
- 8. Add Trypan Blue, 10% by volume of 1% Trypan Blue (w/v) added 3–5 minutes before scoring works well. Score live versus dead cells in a hemacytometer. Cytotoxic Index (C.I.) can be calculated as shown in **Figure 1**.

## **RESULTS - ANTIBODY TITRATION BY CYTOTOXICITY ANALYSIS:**

see FIGURE 2

Cell Source: Splenocytes

Donor: DBA

<u>Cell Concentration</u>: 1.1 x 10e6 cells/ml <u>Complement</u>: Low-Tox-M Rabbit Complement

**Complement Concentration: 1:10** 

#### TISSUE DISTRIBUTION BY CYTOTOXICITY ANALYSIS:

Antibody Concentration used: 1:40

Strain: DBA

#### Cell Source:

Thymus: 0% Spleen: 54% Lymph Node: 16% Bone Marrow: 12%

## STRAIN DISTRIBUTION BY CYTOTOXICITY ANALYSIS:

Antibody Concentration Used: 1:40

Strains Tested: C57BL/6; C3H/He; DBA; A.TH; A.TL

Cells Killed by Treatment: C57BL/6; DBA

Cells Not Killed by Treatment: C3H/He, A.TH; A.TL

# **CYTOTOXIC DEPLETION ASSAY:**

- 1. Prepare a cell suspension from the appropriate tissue (e.g. spleen, lymph node, etc.) in Cytotoxicity Mediuma or equivalent. Remove erythrocytes and dead cells (where necessary) by purification on Lympholyte-M density cell separation mediumb. After washing, adjust the cell concentration to 1.1x10e7 cells per ml in cytotoxicity medium.
- 2. Add the antibody to a final concentration of 1:40.
- 3. Incubate for 60 minutes at 4°C.
- 4. Centrifuge to pellet the cells and discard the supernatant.
- 5. Resuspend to the original volume in cytotoxicity medium containing the appropriate concentration of Low-Tox-M Rabbit Complement3,4.
- 6. Incubate for 60 minutes at 37°C.
- 7. Place on ice and monitor for percent cytotoxicity before further processing. For this purpose, remove a small sample from each tube, dilute 1:10, and add 1/10 volume of 1% Trypan Blue. After 3-5 minutes, score live versus dead cells in a hemacytometer.
- 8. For functional studies, remove dead cells from treated groups before further



processing, particularly if the treated cells are to be cultured. Layering the treated cell suspension over an equal volume of Lympholyte-M cell separation medium and centrifuging, as per the instructions provided, can do this. Live cells will form a layer at the interface, while the dead cells pellet. The interface can then be collected in cytotoxicity medium before being resuspended in the appropriate medium for further processing.

### **FUNCTIONAL ANALYSIS:**

#### Method:

Cells were treated as described in Cytotoxic Depletion Assay. Treated cells and controls were tested for:

- a) the ability to generate plaque-forming cells (PFC) using a modified Jerne haemolytic plaque assay
- b) the ability to generate cytotoxic T effector cells using a cytotoxic lymphocyte reaction (CTL) assay. Cells were treated both before and after sensitization in the CTL assay. In vitro immunizations were used in all experiments.

#### Results:

<u>Cell Source</u>: Splenocytes <u>Donors</u>: C3H/He and BALB/c <u>Cell Concentration</u>: 1x10e7 cells/ml <u>Antibody Concentration</u>: 1:100

Complement: Low-Tox®-M Rabbit Complement

**Complement Concentration: 1:10** 

Treatment of BALB/c splenocytes with CL8713A plus complement resulted in a significant reduction in the number of plaque forming cells. Partial inhibition of cytotoxic T effector cell function as assessed by CTL assay was also noted. Treatment of C3H/He cells had no effect on either plaque forming cell number or cytotoxic T cell function. These results are consistent with the removal of I-Ad bearing cells and their related activities.

## **NOTES:**

- a. Cytotoxicity Medium is RPMI-1640 with 25 mM HEPES buffer and 0.3% bovine serum albumin (BSA). BSA is substituted for the conventionally used fetal calf serum (FCS) because we have found that many batches of FCS contain complement dependent cytotoxins to mouse lymphocytes, thus increasing the background killing in the presence of complement. We recommend that cells not be exposed to FCS prior to or during exposure to antibody and complement. Some batches of BSA also contain complement dependent cytotoxins, resulting in the same problem. We screen for batches of BSA giving low background in the presence of complement and use the selected BSA for preparing Cytotoxicity Medium.
- b. Lympholyte®-M cell separation medium is density separation medium designed specifically for the isolation of viable mouse lymphocytes. This separation medium provides a high and non-selective recovery of viable mouse lymphocytes, removing



red cells and dead cells. The density of this medium is 1.087 - 1.088. Isolation of mouse lymphocytes on cell separation medium of density 1.077 will result in high and selective loss of lymphocytes and should be avoided.

c. Rabbit serum provides the most potent source of complement for use with antibodies to mouse cell surface antigens. However, rabbit serum itself is very toxic to mouse lymphocytes. Low-Tox®-M Rabbit Complement is absorbed to remove toxicity to mouse lymphocytes, while maintaining its high complement activity. When used in conjunction with Cytotoxicity Medium, this reagent provides a highly potent source of complement with minimal background toxicity.

**Pictures:** 

Figure 2.




Figure 1.

C.I. = 100 x % cyt (antibody + complement) - % cyt (complement alone)
100% - % cyt (complement alone)